Back to News
Market Impact: 0.25
Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis
Source: PR Newswire
Healthcare & Biotech
Accro Bioscience announced that it dosed the first patient in a Phase IIb clinical trial for a novel therapeutic targeting immune-mediated diseases. The trial initiation represents a positive clinical-development milestone, although the release provides no efficacy, safety, financial, or enrollment details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- CVS Plans to Break Up $117 Billion Healthcare Conglomerate
- Novo raises full-year outlook as Wegovy sales impress
- How Abdul El-Sayed would build Medicare for All, from a wealth tax to a Fed-style governing board
- BillionToOne SVP John ten Bosch sells $320,723 in stock
- Novo CEO Doustdar 'Very Optimistic' About CagriSema
- Sight Sciences earnings missed by $0.48, revenue topped estimates